11 research outputs found
Sensitivity analysis for the pooled HRs in OS.
<p>The analysis was conducted by estimating the average HR in the absence of each study. HRs = hazard ratios; OS = overall survival.</p
PRISMA flow Chart of literature search and study selection.
<p>PRISMA flow Chart of literature search and study selection.</p
Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis
<div><p>Background</p><p>The prognostic value of circulating tumor cells (CTCs) in ovarian cancer has been investigated in previous studies, but the results are controversial. Therefore we performed a meta-analysis to systematically review these data and evaluate the value of CTCs in ovarian cancer.</p><p>Materials and Methods</p><p>A literary search for relevant studies was performed on Embase, Medline and Web of Science databases. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analyses, sensitivity analyses, meta-regression analyses and publication bias were conducted.</p><p>Results</p><p>This meta-analysis is based on 11 publications and comprises a total of 1129 patients. The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22–2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18–1.75). Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34–3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45–2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62–1.90). The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87–8.85).</p><p>Conclusion</p><p>Our study demonstrates that CTC status is associated with OS and PFS/DFS in ovarian cancer.</p></div
Main results.
<p>HR, hazard ratio; CI, confidence intervals; NOS, Newcastle-Ottawa Scale; OS, overall survival; PFS,progression-free survival; DFS,disease-free survival.</p><p>Main results.</p
Begg’s funnel plots of the prognostic role of CTCs in OS.
<p>CTCs = circulating tumor cells; OS = overall survival.</p
Main characteristics of the eligible studies.
<p><sup>a</sup>Tumor stage and percentage of advanced stage(%); NR, Not Reported; CTCs, circulating tumor cells; ICC, immunocytochemistry; RT-PCR, reverse-transcriptase polymerase chain reaction.</p><p>Main characteristics of the eligible studies.</p
Forest plots of the association between CTCs and CA-125.
<p>CTCs = circulating tumor cells.</p
Forest plot showing the meta-analysis of hazard ratio estimates for OS in “Surgery” subgroup and “Chemotherapy” subgroup.
<p>Subgroup analysis based on different treatment methods. OS = overall survival.</p
Forest plot showing the meta-analysis of hazard ratio estimates for DFS/PFS in overall patients.
<p>DFS = disease-free survival; PFS = progression-free survival.</p
Forest plot showing the meta-analysis of hazard ratio estimates for OS in “Other ICC” subgroup, “Cellsearch” subgroup and “RT-PCR” subgroup.
<p>Subgroup analysis based on different CTC detection methods. OS = overall survival; ICC = immunocytochemistry; RT-PCR = reverse-transcriptase polymerase chain reaction; CTC = circulating tumor cell.</p